Amivantamab for Recurrent or Metastatic Adenoid Cystic Carcinoma

Is amivantamab, a potent epidermal growth factor receptor (EGFR)–mesenchymal–epithelial transition (MET) bispecific antibody, a potential therapeutic option for recurrent/metastatic adenoid cystic carcinoma (ACC)?In this phase 2 nonrandomized clinical trial that evaluated 18 patients, the clinical benefit rate, including complete response, partial response, and stable disease, was 72.2% with amivantamab. Patients tolerated treatment well.This represents one of few clinical trials in advanced ACC to evaluate a dual-targeted therapy; amivantamab warrants further exploration alone or in combination in ACC.

Corresponding Author: Trisha M. Wise-Draper, MD, PhD, Division of Hematology/Oncology, University of Cincinnati, 3125 Eden Ave, Cincinnati, OH 45267 (wiseth@ucmail.uc.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.